What is Vutrisiran? A Comprehensive Guide to a Gene-Silencing Therapy
•
4 min read
First approved in 2022 for hereditary transthyretin-mediated amyloidosis (hATTR) with polyneuropathy, **vutrisiran** (brand name Amvuttra) is a gene-silencing medication that offers a new approach to treatment. It works by targeting the root genetic cause of the disease, preventing the production of the toxic protein that causes nerve and heart damage.
